Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
Stocks · News reference
Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroupsNew
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8 Of 11 Sectors Fall Wednesday As Defensives Lead
Three sectors are higher and eight are lower in Wednesday's regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single sector pulling away from the group.
AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment
AbbVie today announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with SKYRIZI® (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease (CD).
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.